, Tracking Stock Market Picks
Enter Symbol:
Rating: PCRX
Overweight $115
down 3.00 %

Pacira Pharmaceuticals Inc (NASDAQ: PCRX) reiterated to Overweight with price target $115 by Barclays

Tuesday,  Mar 3, 2015  2:25 PM ET by Lynn Gilbert

Barclays reiterated Pacira Pharmaceuticals Inc (NASDAQ: PCRX) to Overweight with price target $115. Previously, Barclays rated Pacira Pharmaceuticals Inc (NASDAQ: PCRX) to Overweight with price
target $127 on 03/02/2015, when the stock price was valued at $94.64. Since then, Pacira Pharmaceuticals Inc's stock price has lost 3% as of 03/03/2015's recent price of $91.92.
If you had followed Barclays's previous recommendation on PCRX, you would have lost 3% of your investment in 1 days.

Pacira Pharmaceuticals, Inc. (Pacira), formerly Pacira, Inc., is the holding company for the Company?s California operating subsidiary of the same name, which it refers to as PPI-California. The Company is a specialty pharmaceutical company focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its product candidate EXPAREL is a long-acting bupivacaine (anesthetic/analgesic) product for postsurgical pain management. EXPAREL provides analgesia for up to 72 hours post-surgery. EXPAREL consists of bupivacaine encapsulated in DepoFoam. DepoFoam, its extended release drug delivery technology, is the basis for its commercial products: DepoCyt(e) and DepoDur, which it manufactures for its commercial partners. Its product portfolio and product candidate pipeline include EXPAREL, DepoCyt, DepoDur, DepoNSAID and DepoMethotrexate.


RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy